Stagno, F.; Stella, S.; Leotta, S.; Caserta, S.; Vitale, S.R.; Markovic, U.; Tomarchio, C.; Mirabile, G.; Russo, S.; Massimino, M.;
et al. No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level. Int. J. Mol. Sci. 2025, 26, 1840.
https://doi.org/10.3390/ijms26051840
AMA Style
Stagno F, Stella S, Leotta S, Caserta S, Vitale SR, Markovic U, Tomarchio C, Mirabile G, Russo S, Massimino M,
et al. No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level. International Journal of Molecular Sciences. 2025; 26(5):1840.
https://doi.org/10.3390/ijms26051840
Chicago/Turabian Style
Stagno, Fabio, Stefania Stella, Salvatore Leotta, Santino Caserta, Silvia Rita Vitale, Uros Markovic, Cristina Tomarchio, Giuseppe Mirabile, Sabina Russo, Michele Massimino,
and et al. 2025. "No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level" International Journal of Molecular Sciences 26, no. 5: 1840.
https://doi.org/10.3390/ijms26051840
APA Style
Stagno, F., Stella, S., Leotta, S., Caserta, S., Vitale, S. R., Markovic, U., Tomarchio, C., Mirabile, G., Russo, S., Massimino, M., Vigneri, P., Manzella, L., Di Raimondo, F., & Allegra, A.
(2025). No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level. International Journal of Molecular Sciences, 26(5), 1840.
https://doi.org/10.3390/ijms26051840
